Home
This site is intended for healthcare professionals
Sign upLog in

Key Clinical Summary: Optimizing Obstructive Sleep Apnea Management: SLEEP Highlights

This is a summary of Enduring Module presented by expert Dr Charlene Gamaldo which you can find here:
Optimizing Obstructive Sleep Apnea Management: SLEEP Highlights
Before participating, please read our CME and disclosure information which can be found in all of the links above.

This program is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals in the US.

Patient-Specific Evaluation and PAP Escalation Criteria

  • Assessment of PAP Appropriateness: Positive airway pressure (PAP) remains an effective treatment for obstructive sleep apnea (OSA) because it prevents upper-airway collapse regardless of underlying endotype. Its real-world effectiveness, however, depends on adequate use and tolerability. Mask discomfort, pressure intolerance, nasal symptoms, and aerophagia may reduce treatment persistence.
  • When to Consider Escalation: Alternative or combination strategies should be considered when PAP remains ineffective, cannot be used adequately, or remains unacceptable despite appropriate troubleshooting and optimization. Persistent symptoms, residual OSA, treatment burden, and patient preferences should all inform the decision.
  • Factors Associated With Progression to Non-PAP Evaluation:
    • Symptom burden: Higher Epworth Sleepiness Scale and Insomnia Severity Index scores have been associated with progression to drug-induced sleep endoscopy (DISE) and/or surgical evaluation.
    • Clinical factors: Lower BMI and previous mandibular advancement device use have been associated with progression toward DISE or surgery in PAP-intolerant patients.
    • Decision support: Patients who feel informed, clear about their treatment goals, and supported in weighing benefits and burdens may be better positioned to make decisions about alternative treatment options.

Selection, Sequencing, and Combination of Non-PAP Therapies

  • Endotype-Guided Selection: OSA endotypes may help inform selection of non-PAP therapies, although prospective validation of endotype-guided treatment strategies is still needed.
    • Anatomical upper-airway collapsibility: Potential approaches include weight-loss interventions, oral appliance therapy, upper-airway surgery, and positional therapy.
    • High loop gain: Potential approaches include supplemental oxygen in selected patients and off-label acetazolamide.
    • Low respiratory arousal threshold: Potential approaches include off-label hypnotic therapy, such as trazodone, and cognitive behavioral therapy for insomnia.
    • Ineffective upper-airway muscle responsiveness: Potential approaches include hypoglossal nerve stimulation, pharyngeal muscle training, and investigational pharmacotherapy.
  • Physiologic Phenotypes and Cardiovascular Risk: High hypoxic burden and greater heart-rate response have been associated with increased rates of major adverse cardiovascular events and cardiovascular death. Mandibular advancement devices, hypoglossal nerve stimulation, and tirzepatide have been shown to reduce hypoxic burden, while the effects of CPAP vary according to treatment adherence.
  • Therapy Sequencing and Combination: When a single non-PAP therapy provides only partial control, combining complementary treatments may be appropriate. For example, residual supine OSA after a beneficial response to a mandibular advancement device may be addressed by adding positional therapy rather than moving immediately to a more invasive option.

Integration of Weight Management Into OSA Care Pathways

  • Relationship Between Obesity and OSA: Obesity is associated with increased upper-airway collapsibility and changes in ventilatory physiology that may influence OSA severity and expression.
  • Role of Anti-Obesity Pharmacotherapy: Tirzepatide is FDA-approved for adults with obesity (BMI ≥30 kg/m²) and moderate-to-severe OSA (AHI ≥15 events/hour), alongside a reduced-calorie diet and increased physical activity. . Response may vary between patients and can be difficult to predict. Weight management should be integrated as an adjunct to ongoing OSA treatment rather than viewed as a replacement for effective OSA therapy.
  • Tirzepatide Use:
    • Treatment is initiated at 2.5 mg once weekly and increased as tolerated.
    • Gastrointestinal adverse effects such as nausea, vomiting, diarrhea, constipation, and gastroesophageal reflux may occur, particularly during dose escalation.
    • Tolerability should be actively managed through strategies such as adjusting the pace of dose escalation and recommending smaller meals to reduce gastrointestinal symptoms. Treatment response should not be judged prematurely during titration.
    • Clinical factors, contraindications, and relevant safety considerations should be reviewed before and during treatment.
  • Integrated Care: Sleep specialists should initiate discussions about weight management and coordinate treatment with primary care or other appropriate services according to patient needs and local resources. Shared-care models can allow weight treatment and OSA management to proceed in parallel.

Longitudinal Reassessment, Adherence, and Decision-Making

  • Structured Follow-Up: OSA follow-up should include assessment of treatment adherence, residual AHI, usage, leak, daytime sleepiness, and weight trajectory. During anti-obesity medication initiation and titration, approximately four-weekly touchpoints should assess efficacy, tolerability, affordability, concurrent medications, and behavioral support. Monitoring can be coordinated with primary care or other multidisciplinary team members, including through telehealth, according to patient needs and local resources.
  • Repeat Sleep Testing:
    • Repeat testing may be considered after a clinically meaningful weight change, particularly after approximately 10% to 20% weight reduction or gain.
    • Testing is most informative after weight has stabilized rather than during active weight loss.
    • Reassessment is particularly important before discontinuing PAP or switching to an alternative OSA treatment.
    • Auto-adjusting PAP may reduce the need for repeated pressure titration during active weight change in uncomplicated OSA.
  • Weight Change and OSA Severity: A 10% reduction in body weight has been associated with an average reduction in AHI of approximately 26%, while a 10% weight gain has been associated with an increase in AHI of approximately 32%.
  • Long-Term Treatment Persistence: Discontinuation of anti-obesity medication may lead to weight regain and worsening OSA. Reaching a weight-loss goal should therefore prompt structured reassessment rather than unplanned discontinuation of weight-management or OSA therapy.
  • Behavioral Reinforcement: Pharmacologic weight management should be accompanied by lifestyle support. Adequate protein intake and resistance exercise may help preserve lean mass during weight loss.